|
News for Healthier Living
ESMO: Novel ADC AZD8205 Demonstrates Manageable Safety Profile and Preliminary Efficacy in First-in-Human Trial
The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.
September 13, 2024
September 15 2024September 14 2024September 13 2024September 12 2024September 11 2024September 10 2024September 9 2024September 8 2024September 7 2024September 6 2024September 5 2024September 4 2024September 3 2024September 2 2024
|
|
|
|
|